The FDA approved Lipfendra (enlicitide) on July 17, 2026, the first oral PCSK9 inhibitor for lowering LDL cholesterol in adults with high cholesterol, according to an FDA announcement. Taken once daily as a pill, the Merck drug reduced LDL cholesterol by nearly 60 percent in clinical testing, per trial data reported around the approval.
Newspaper Daily publishes information, not medical advice. The outlet reports on regulatory actions and research findings and does not provide diagnosis or treatment guidance.
Why a pill matters
PCSK9 inhibitors have been available only as injections, typically every two weeks or monthly, and their cost and delivery format have limited use. An oral option lowers the barrier for adults who need LDL reductions beyond what statins provide, including people with heterozygous familial hypercholesterolemia, an inherited form of very high cholesterol that the indication covers.
The drug works by a different mechanism than statins: PCSK9 inhibitors help the liver clear LDL from the blood, and enlicitide achieves this orally by disrupting the interaction that would otherwise send LDL receptors to the cellular recycling bin.
Related stories: FDA Approves First Oral Antiviral to Prevent COVID-19 After Exposure · FDA Approves Foundayo, an Oral GLP-1 Pill for Weight Management.
What this approval can and cannot show
Approval establishes that enlicitide lowers LDL cholesterol substantially. It does not by itself prove that the pill reduces heart attacks or strokes; outcome trials for the PCSK9 class as a whole have shown cardiovascular benefit for the injectables, but oral enlicitide's own outcomes data remain limited, and the trials that supported approval ran for months, not years. Long-term safety, drug interactions, and adherence in routine care also need post-approval study.
The FDA's announcement did not set a launch date, and Merck had not published United States pricing at the time of clearance, leaving access questions open.
When to talk to a clinician
Adults whose LDL remains above target despite a statin, or who cannot tolerate statins, can ask whether adding a PCSK9 inhibitor fits their risk profile. Switching or adding therapies should be guided by lipid testing and overall cardiovascular risk, not by LDL numbers alone.